Cadrenal Therapeutics Gets FDA Orphan Drug Designation for Tecarfarin

By Chris Wack

Cadrenal Therapeutics said that the U.S. Food and Drug Administration has granted tecarfarin orphan drug designation for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device.

This is the second orphan drug designation for tecarfarin.

The FDA's ODD program provides incentives to sponsor organizations for the development of innovative treatments for rare diseases that affect fewer than 200,000 people in the U.S.

These patients require chronic anticoagulation to prevent the formation of thrombus,or a clot, which can cause the device to fail or can result in a clot breaking off, resulting in a stroke or other vascular catastrophe.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

04-09-24 0924ET